Other Events ·
Larimar Therapeutics, Inc. announced on June 29, 2026, that it has submitted the first module of a rolling Biologics…
LRMRLarimar Therapeutics, Inc.
Larimar Therapeutics, Inc. announced on June 29, 2026, that it has submitted the first module of a rolling Biologics License Application (BLA) rolling submission to the FDA for the accelerated approval of nomlabofusp. Additionally, the following long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich's ataxia was reported to have yielded positive data. Larimar Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.